Startups, Pharma

M3 Biotechnology raises $10M for drugs that “can regrow brain cells”

The regenerative medicine company says it has a small molecule in the works that could help regrow brain cells in Alzheimer's and Parkinson's disease.

 

brainSeattle-based M3 Biotechnology just closed out an oversubscribed $10 million Series A for its regenerative medicine company that has broad claims: It purports its small molecule drugs “can regrow brain cells” – reversing diseases like Alzheimer’s and Parkinson’s.

Funding will move the company towards clinical trials for its lead compound, MM-201 – an oral drug that works as a growth factor to spur an increase in neuronal connections.

Investors include WRF Capital, the W-Fund and prolific drug developers – and brothers – Bruce and Michael Montgomery.

Photo: Flickr user Liz Henry

Shares0
Shares0